Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CP-778, 875 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| CP-778,875 | DRUG | - |
Inclusion Criteria: * HDL-C \< or = 45 mg/dL for men and \< or = 55 mg/dL for women * Triglycerides between 150-500 mg/dL * Fasting Plasma Glucose 140-240 mg/dL Exclusion Criteria: * Known cardiovascular, carotid, or peripheral vascular disease
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 2 | PHASE3 | Lepodisiran |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Enlicitide, Rosuvastatin |
| NewAmsterdam Pharma Company N.V. | NAMS | 3 | PHASE3 | obicetrapib, ezetimibe daily |
| AstraZeneca PLC | AZN | 3 | PHASE2 | AZD0780, Rosuvastatin |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE1 | ARO-DIMERPA |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX310 |
| HeartFlow, Inc. | HTFL | 1 | N/A | Rosuvastatin |
CP-778,875 is an investigational small molecule being studied for the treatment of dyslipidemia, a condition characterized by abnormal lipid levels in the blood. It is being developed by Pfizer, Inc. (PFE) and is currently in Phase 2 clinical development.
CP-778,875 is a small molecule being developed for dyslipidemia. Its specific molecular target has not been disclosed in available information, so its exact mechanism of action is not publicly detailed.
CP-778,875 is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 2 clinical development for dyslipidemia.
CP-778,875 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 clinical trial has been completed to evaluate its effects.
CP-778,875 has been studied in one completed Phase 2 clinical trial, identified as NCT00326326. This trial evaluated the effect of CP-778,875 on HDL-C in subjects with abnormal lipid levels and type 2 diabetes. The trial enrolled 84 participants in the United States.
CP-778,875 is a unique investigational compound developed by Pfizer, Inc. No alternative names for this drug have been disclosed in available information.